EUVIMEDEUVIMED entdecken
Crossref

New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients

Akikazu Kawase

AME Clinical Trials Review · 2024

DOI: 10.21037/actr-23-28 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Akikazu Kawase.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kawase, A. (2024). New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-28

Vancouver

Kawase A. New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients. AME Clinical Trials Review. 2024. doi:10.21037/actr-23-28

BibTeX
@article{Kawase2024,
  author = {Kawase, Akikazu},
  title = {New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients},
  journal = {AME Clinical Trials Review},
  year = {2024},
  doi = {10.21037/actr-23-28}
}
Kostenlos starten →